Stephanie Mu-Lian Woo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Stephanie Mu-Lian Woo has a total of 34 co-authors. Here are the top co-authors by number of shared publications:
- Daniel T. Gildea
Virginia Commonwealth University Health, Department of Gastroenterology, Hepatology, and Nutrition, Richmond, VA
2 shared publications Ahmad Nakshabandi
1 shared publicationAhmed A. Alsaiari
1 shared publication- Aiwu Ruth He
Department of Hematology/Oncology, Medstar Georgetown University Hospital, Washington, DC 20007, USA
1 shared publication - Alexandra V. Kimchy
Department of Gastroenterology, MedStar Georgetown University Hospital, Washington, DC, USA
1 shared publication Amol S Rangnekar
Medstar Georgetown Transplant Institute, Medstar Georgetown University Hospital, Washington, DC, USA
1 shared publication
Latest Publications
- Open Access
Herbal- and Dietary-Supplement-Induced Liver Injury: A Review of the Recent Literature
Herbal-induced liver injury (HILI) continues to increase in prevalence each year due to the ongoing popularity of herbal supplements and complementary and alternative medicines. A detailed literature review of case reports and clinical studies published from March 2021 to March 2023 was performed. We discuss the epidemiology and diagnosis of HILI as well as the current and proposed laws and regulations. The 2021 ACG guidelines and 2022 AASLD practice guidelines for the diagnosis and management of drug and herbal-induced liver injury are discussed. We describe updates to previously reported etiologies of HILI such as ayurveda, ashwagandha, turmeric, kratom, green tea extract, and garcinia cambogia. Newly described supplements resulting in HILI, such as tinospora cordifolia, horse chestnut, alkaline water, and more, are described. We discuss newly and previously identified hepatoprotective herbal supplements as they have been reported in the study of animal models and human liver cells. This review suggests the need for ongoing research on the causes and mechanisms of HILI to ensure its proper diagnosis, prevention, and treatment in the future. The goal of this review is to provide novice and expert readers with knowledge regarding the possible etiologies of HILI and a general overview.
Open AccessHerbal- and Dietary-Supplement-Induced Liver Injury: A Review of the Recent Literature
Herbal-induced liver injury (HILI) continues to increase in prevalence each year due to the ongoing popularity of herbal supplements and complementary and alternative medicines. A detailed literature review of case reports and clinical studies published from March 2021 to March 2023 was performed. We discuss the epidemiology and diagnosis of HILI as well as the current and proposed laws and regulations. The 2021 ACG guidelines and 2022 AASLD practice guidelines for the diagnosis and management of drug and herbal-induced liver injury are discussed. We describe updates to previously reported etiologies of HILI such as ayurveda, ashwagandha, turmeric, kratom, green tea extract, and garcinia cambogia. Newly described supplements resulting in HILI, such as tinospora cordifolia, horse chestnut, alkaline water, and more, are described. We discuss newly and previously identified hepatoprotective herbal supplements as they have been reported in the study of animal models and human liver cells. This review suggests the need for ongoing research on the causes and mechanisms of HILI to ensure its proper diagnosis, prevention, and treatment in the future. The goal of this review is to provide novice and expert readers with knowledge regarding the possible etiologies of HILI and a general overview.
- Open Access
- 1 April 2023
- Published by AME Publishing Company in Translational Gastroenterology and Hepatology
- Vol. 8, 15
Clinical outcomes: endoscopic resection of duodenal ampullary lesions
Original Article Clinical outcomes: endoscopic resection of duodenal ampullary lesions Stephanie M. Woo, Mark J. Real, Brett M. Will, Eric J. Kim, Jiling Chou, Ahmed A. Alsaiari, Ahmad Nakshabandi, Walid M. Chalhoub, Nadim G. Haddad
- 1 April 2023
- Published by AME Publishing Company in Translational Gastroenterology and Hepatology
- Vol. 8, 15
Open AccessClinical outcomes: endoscopic resection of duodenal ampullary lesions
Original Article Clinical outcomes: endoscopic resection of duodenal ampullary lesions Stephanie M. Woo, Mark J. Real, Brett M. Will, Eric J. Kim, Jiling Chou, Ahmed A. Alsaiari, Ahmad Nakshabandi, Walid M. Chalhoub, Nadim G. Haddad
- Open Access
- 1 February 2023
- Published by Taylor & Francis in Hepatic Medicine: Evidence and Research
- Vol. ume 15, 1-9
COVID-19-Associated Liver Injury
This review analyzes data regarding liver injury associated with COVID-19 infection. We discuss reported effects on the liver from both COVID-19 and COVID-19 treatment as well as pathophysiology, review the potential role of drug-induced liver injury as an etiology of COVID-19-associated liver injury, and touch on other reports of significant outcomes including COVID-19 cholangiopathy and autoimmune hepatitis. Finally, we review the implications of COVID-19 infection in liver transplant recipients.
- 1 February 2023
- Published by Taylor & Francis in Hepatic Medicine: Evidence and Research
- Vol. ume 15, 1-9
Open AccessCOVID-19-Associated Liver Injury
This review analyzes data regarding liver injury associated with COVID-19 infection. We discuss reported effects on the liver from both COVID-19 and COVID-19 treatment as well as pathophysiology, review the potential role of drug-induced liver injury as an etiology of COVID-19-associated liver injury, and touch on other reports of significant outcomes including COVID-19 cholangiopathy and autoimmune hepatitis. Finally, we review the implications of COVID-19 infection in liver transplant recipients.
- Open Access
- 13 December 2022
- Published by MDPI AG in Current Oncology
- Vol. 29 (12) , 9813-9825
Immunotherapy Use Prior to Liver Transplant in Patients with Hepatocellular Carcinoma
Hepatocellular carcinoma (HCC) is the fourth leading cause of cancer-related mortality worldwide, and its incidence has increased rapidly in the United States over the past two decades. Liver transplant is considered curative, but is not always possible, and pre-transplant immunotherapy is of great interest as a modality for downstaging the tumor burden. We present a review of the literature on pre-liver transplant immunotherapy use in patients with HCC. Our literature search queried publications in Ovid MEDLINE, Ovid Embase, and Web of Science, and ultimately identified 24 original research publications to be included for analysis. We found that the role of PD-1 and PD-L1 in risk stratification for rejection is of special interest to researchers, and ongoing randomized clinical trials PLENTY and Dulect 2020-1 will provide insight into the role of PD-1 and PD-L1 in liver transplant management in the future. This literature search and the resulting review represents the most thorough collection, analysis, and presentation of the literature on the subject to date.
- 13 December 2022
- Published by MDPI AG in Current Oncology
- Vol. 29 (12) , 9813-9825
Open AccessImmunotherapy Use Prior to Liver Transplant in Patients with Hepatocellular Carcinoma
Hepatocellular carcinoma (HCC) is the fourth leading cause of cancer-related mortality worldwide, and its incidence has increased rapidly in the United States over the past two decades. Liver transplant is considered curative, but is not always possible, and pre-transplant immunotherapy is of great interest as a modality for downstaging the tumor burden. We present a review of the literature on pre-liver transplant immunotherapy use in patients with HCC. Our literature search queried publications in Ovid MEDLINE, Ovid Embase, and Web of Science, and ultimately identified 24 original research publications to be included for analysis. We found that the role of PD-1 and PD-L1 in risk stratification for rejection is of special interest to researchers, and ongoing randomized clinical trials PLENTY and Dulect 2020-1 will provide insight into the role of PD-1 and PD-L1 in liver transplant management in the future. This literature search and the resulting review represents the most thorough collection, analysis, and presentation of the literature on the subject to date.
- Open Access
- 27 September 2021
- Published by Baishideng Publishing Group Inc. in World Journal of Hepatology
- Vol. 13 (9) , 1019-1041
Herbal and dietary supplement induced liver injury: Highlights from the recent literature
Herbal and dietary supplement induced liver injury: Highlights from the recent literature
- 27 September 2021
- Published by Baishideng Publishing Group Inc. in World Journal of Hepatology
- Vol. 13 (9) , 1019-1041
Open AccessHerbal and dietary supplement induced liver injury: Highlights from the recent literature
Herbal and dietary supplement induced liver injury: Highlights from the recent literature
- Open Access
- 1 December 2013
- Published by Taylor & Francis in Patient Preference and Adherence
- Vol. 8, 25-30
Strategies for changing negative public attitudes toward organ donation in the People's Republic of China
Peer reviewed article authored by (Shumin X, Woo SM, Lei Z). Read article or submit your manuscript for publishing.
- 1 December 2013
- Published by Taylor & Francis in Patient Preference and Adherence
- Vol. 8, 25-30
Open AccessStrategies for changing negative public attitudes toward organ donation in the People's Republic of China
Peer reviewed article authored by (Shumin X, Woo SM, Lei Z). Read article or submit your manuscript for publishing.
- Open Access
- 1 November 2013
- Published by Taylor & Francis in Patient Preference and Adherence
- Vol. 7, 1157-1162
A study of patient experience and perception regarding postoperative pain management in Chinese hospitals
Background: This study aims to analyze the current status of postoperative pain management in the People's Republic of China's provincial-level hospitals, and the existing knowledge and opinions held by patients regarding these methods. Methods: The 128 participants in this study were urology and hepatobiliary patients from three provincial-level hospitals in Hunan. The questionnaire assessing postoperative pain was designed using the typical pain assessment scales and pain management guidelines as references. Results: 82.8% of study participants claimed that their postoperative pain was relieved within 3 days of their operations. However, while 91.4% of surveyed patients experienced moderate to severe pain, 51.6% received no treatment for their postoperative pain, and 14.9% complained that medical personnel failed to manage their pain. 20.2% were unsatisfied with their pain management, indicating that treatment did not meet their expectations. Furthermore, participants demonstrated a great misunderstanding of pain and analgesics, as 72.6% of patients were unfamiliar with morphine, 51.6% of patients believed only certain types of pain required management, and 18.5% refused to use morphine. Conclusion: In most Chinese provincial-level hospitals, current postoperative pain management methods are able to alleviate the pain experienced by the majority of patients, though pain assessment and therapy procedures are still not standardized. Furthermore, most patients lack a proper understanding of postoperative pain and analgesics. Therefore, pain management education for doctors and patients and their relatives should be implemented in order to improve the quality of postoperative pain management.
- 1 November 2013
- Published by Taylor & Francis in Patient Preference and Adherence
- Vol. 7, 1157-1162
Open AccessA study of patient experience and perception regarding postoperative pain management in Chinese hospitals
Background: This study aims to analyze the current status of postoperative pain management in the People's Republic of China's provincial-level hospitals, and the existing knowledge and opinions held by patients regarding these methods. Methods: The 128 participants in this study were urology and hepatobiliary patients from three provincial-level hospitals in Hunan. The questionnaire assessing postoperative pain was designed using the typical pain assessment scales and pain management guidelines as references. Results: 82.8% of study participants claimed that their postoperative pain was relieved within 3 days of their operations. However, while 91.4% of surveyed patients experienced moderate to severe pain, 51.6% received no treatment for their postoperative pain, and 14.9% complained that medical personnel failed to manage their pain. 20.2% were unsatisfied with their pain management, indicating that treatment did not meet their expectations. Furthermore, participants demonstrated a great misunderstanding of pain and analgesics, as 72.6% of patients were unfamiliar with morphine, 51.6% of patients believed only certain types of pain required management, and 18.5% refused to use morphine. Conclusion: In most Chinese provincial-level hospitals, current postoperative pain management methods are able to alleviate the pain experienced by the majority of patients, though pain assessment and therapy procedures are still not standardized. Furthermore, most patients lack a proper understanding of postoperative pain and analgesics. Therefore, pain management education for doctors and patients and their relatives should be implemented in order to improve the quality of postoperative pain management.